CG Oncology, Inc. Common stock (CGON)
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
CGON Insider Trading Activity
CGON Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $19,749,652 | 6 | 100 |
Related Transactions
| POST LEONARD E | director | 0 | $0 | 5 | $149,652 | $-149,652 |
| Song Hong Fang | director | 0 | $0 | 1 | $19.6M | $-19.6M |
About CG Oncology, Inc. Common stock
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.
Insider Activity of CG Oncology, Inc. Common stock
Over the last 12 months, insiders at CG Oncology, Inc. Common stock have bought $0 and sold $19.75M worth of CG Oncology, Inc. Common stock stock.
On average, over the past 5 years, insiders at CG Oncology, Inc. Common stock have bought $7.6M and sold $19.75M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 400,000 shares for transaction amount of $7.6M was made by Decheng Capital Global Life Sciences Fund IV, L.P. (10 percent owner) on 2024‑01‑29.
List of Insider Buy and Sell Transactions, CG Oncology, Inc. Common stock
| 2025-03-17 | Sale | POST LEONARD E | director | 1,000 0.0013% | $28.00 | $28,000 | -0.05% | |
| 2025-02-18 | Sale | POST LEONARD E | director | 1,000 0.0013% | $28.61 | $28,610 | -7.57% | |
| 2025-01-13 | Sale | POST LEONARD E | director | 1,000 0.0014% | $29.66 | $29,660 | -2.48% | |
| 2024-12-16 | Sale | Song Hong Fang | director | 700,000 1.0073% | $28.00 | $19.6M | -2.43% | |
| 2024-12-16 | Sale | POST LEONARD E | director | 1,000 0.0015% | $28.84 | $28,840 | -2.43% | |
| 2024-12-06 | Sale | POST LEONARD E | director | 1,000 0.0015% | $34.54 | $34,542 | -17.32% | |
| 2024-01-29 | Decheng Capital Global Life Sciences Fund IV, L.P. | 10 percent owner | 400,000 0.3234% | $19.00 | $7.6M | -4.05% |
Insider Historical Profitability
| Song Hong Fang | director | 3003931 3.9099% | $82.73M | 0 | 1 | |
| POST LEONARD E | director | 0 0% | $0 | 0 | 5 | |
| Decheng Capital Global Life Sciences Fund IV, L.P. | 10 percent owner | 400000 0.5206% | $11.02M | 1 | 0 | <0.0001% |
Historical Insider Profitability vs. Competitors
$66,492,695 | 135 | 27.65% | $2.11B | |
$1,376,668 | 53 | 18.46% | $2.4B | |
$11,583,737 | 45 | 49.75% | $1.86B | |
$224,319,161 | 41 | 27.46% | $2.31B | |
$62,927,079 | 29 | 14.02% | $2.3B | |
$150,253,463 | 26 | -52.83% | $2.1B | |
$1,801,511 | 23 | 18.58% | $2.02B | |
$92,580,864 | 14 | -1.28% | $2.17B | |
$75,296,816 | 12 | 37.23% | $2.07B | |
$137,013,690 | 11 | 26.62% | $2.03B | |
$117,959,652 | 9 | -12.47% | $2.51B | |
$55,713,031 | 8 | -0.36% | $2.34B | |
$32,575,266 | 8 | 37.03% | $2.14B | |
$25,073,947 | 7 | -5.99% | $1.89B | |
$10,000,009 | 1 | 100.92% | $1.82B | |
$9,900,000 | 1 | -7.19% | $2.05B | |
CG Oncology, Inc. Common stock (CGON) | $7,600,000 | 1 | -4.05% | $2.12B |
$95,000 | 1 | -0.78% | $2.57B | |
$49,999,992 | 1 | 50.02% | $2.37B |
CGON Institutional Investors: Active Positions
| Increased Positions | 96 | +91.43% | 19M | +36.91% |
| Decreased Positions | 44 | -41.9% | 5M | -10.08% |
| New Positions | 38 | New | 5M | New |
| Sold Out Positions | 17 | Sold Out | 3M | Sold Out |
| Total Postitions | 157 | +49.52% | 66M | +26.83% |
CGON Ownership Change vs Market
Institutional Investor Ownership
| Decheng Capital Llc | $172,354.00 | 8.5% | 6.37M | +892,859 | +16.3% | 2024-12-31 |
| Vanguard Group Inc | $158,542.00 | 7.82% | 5.86M | +779,730 | +15.35% | 2024-12-31 |
| Blackrock, Inc. | $109,854.00 | 5.42% | 4.06M | +490,203 | +13.73% | 2024-12-31 |
| Tcg Crossover Management, Llc | $99,279.00 | 4.89% | 3.67M | 0 | 0% | 2024-12-31 |
| Braidwell Lp | $88,814.00 | 4.38% | 3.28M | +112,442 | +3.55% | 2024-12-31 |
| Kynam Capital Management, Lp | $68,158.00 | 3.36% | 2.52M | +748,900 | +42.29% | 2024-12-31 |
| Fmr Llc | $65,829.00 | 3.25% | 2.43M | +2M | +1,571.36% | 2024-12-31 |
| Foresite Capital Management Vi Llc | $60,091.00 | 2.96% | 2.22M | +2M | New | 2024-12-31 |
| State Street Corp | $52,033.00 | 2.57% | 1.92M | +222,931 | +13.11% | 2024-12-31 |
| Wellington Management Group Llp | $51,678.00 | 2.55% | 1.91M | +1M | +274.44% | 2024-12-31 |